Table 1.
Baseline characteristics of the patients enrolled in the study
| Variable | SGLT-2i treated patients (n = 177) | Never SGLT-2i users (n = 200) | p-value |
|---|---|---|---|
| Age (years) | 66.2 ± 6.3 | 65.4 ± 6.1 | 0.416 |
| BMI (kg/m2) | 28.2 ± 2.2 | 28.0 ± 1.8 | 0.887 |
| Male, n (%) | 115 (65.0) | 128 (64) | 0.465 |
| STEMI, n (%) | 99 (55.9) | 111 (55.5) | 0.245 |
| Diabetes duration, (years) | 15.4 ± 3.2 | 14.9 ± 3.4 | 0.224 |
| Hypertension, n (%) | 97 (54.8) | 110 (55.0) | 0.526 |
| Dyslipidemia, n (%) | 70 (39.5) | 73 (36.5) | 0.595 |
| Previous CVD, n (%) | 58 (32.8) | 63 (31.5) | 0.439 |
| Smokers, n (%) | 29 (16.4) | 33 (16.5) | 0.544 |
| Retinopathy, n (%) | 30 (16.9) | 34 (17.0) | 0.437 |
| Neuropathy, n (%) | 37 (20.9) | 41 (20.5) | 0.511 |
| Admission therapy | |||
| Metformin, n (%) | 106 (59.5) | 119 (59.9) | 0.512 |
| DPP-IV inhibitors, n (%) | 44 (24.9) | 50 (25.0) | 0.535 |
| GLP-1 agonists, n (%) | 19 (10.7) | 22 (11.0) | 0.504 |
| Sulfonylureas, n (%) | 37 (20.9) | 42 (21.0) | 0.442 |
| Thiazolidinediones, n (%) | 8 (4.5) | 10 (5.0) | 0.511 |
| Insulin, n (%) | 53 (29.9) | 61 (30.5) | 0.451 |
| Multiple glucose-lowering drugs, n (%) | 162 (91.5) | 184 (92.0) | 0.507 |
| ACE inhibitors, n (%) | 53 (29.9) | 57 (28.5) | 0.254 |
| ARBs, n (%) | 36 (20.3) | 38 (19.0) | 0.421 |
| Beta-blockers, n (%) | 62 (35.0) | 74 (37.0) | 0.386 |
| Diuretics, n (%) | 18 (10.2) | 21 (10.5) | 0.167 |
| Calcium channel blockers, n (%) | 10 (5.6) | 12 (6.0) | 0.305 |
| Antiplatelet drugs, n (%) | 117 (66.7) | 134 (67.0) | 0.466 |
| Heparin, n (%) | 6 (3.4) | 8 (4.0) | 0.397 |
| Statin, n (%) | 120 (67.8) | 139 (69.5) | 0.336 |
| Systolic blood pressure (mmHg) | 124.1 ± 8.6 | 124.0 ± 12.2 | 0.885 |
| Diastolic blood pressure (mmHg) | 78.6 ± 6.3 | 78.3 ± 6.3 | 0.587 |
| Heart rate | 83.5 ± 8.9 | 84.6 ± 10.5 | 0.587 |
| Hba1c baseline | 6.5 ± 1.6 | 6.3 ± 1.7 | 0.295 |
| HbA1c 3 months | 6.6 ± 0.7 | 6.6 ± 0.7 | 0.29 |
| HbA1c 6 months | 6.6 ± 0.7 | 6.6 ± 0.7 | 0.17 |
| HbA1c 9 months | 8.2 ± 1.2 | 8.1 ± 1.3 | 0.168 |
| HbA1c 12 months | 6.8 ± 0.7 | 6.9 ± 1.3 | 0.987 |
| HbA1c 1-year mean | 6.8 ± 0.5 | 6.9 ± 0.6 | 0.987 |
| Total cholesterol (mg/dL) | 179.6 ± 22.4 | 182.7 ± 15.3 | 0.764 |
| LDL cholesterol (mg/dL) | 104.5 ± 31.1 | 106.9 ± 18.1 | 0.763 |
| HDL cholesterol (mg/dL) | 39.9 ± 3.9 | 39.5 ± 3.5 | 0.596 |
| Triglycerides (mg/dL) | 183.4 ± 20.8 | 181.6 ± 24.1 | 0.594 |
| Creatinine (mg/dL) | 1.0 ± 0.1 | 1.0 ± 0.2 | 0.65 |
| CK-MB (IU/L) | 128.0 ± 7.9 | 127.9 ± 9.2 | 0.638 |
| Troponin (ng/L) | 37.4 ± 3.5 | 37.7 ± 3.6 | 0.129 |
| NT-proBNP (pg/mL) | 20696.0 ± 2119.7 | 20605.0 ± 2370.2 | 0.125 |
| CRP (mg/dL) | 14.8 ± 1.4 | 14.7 ± 1.3 | 0.124 |
| Glucose (mg/dL) | 150.6 ± 54.0 | 157.0 ± 51.7 | 0.133 |
| Stenosis (%) | 69.3 ± 5.9 | 69.8 ± 6.0 | 0.353 |
| MLD (mm) | 1.1 ± 0.2 | 1.1 ± 0.1 | 0.282 |
| Post-stent MLD (mm) | 2.5 ± 0.4 | 2.5 ± 0.3 | 0.441 |
| Lesion length | 21.4 ± 1.9 | 21.3 ± 2.1 | 0.368 |
| Ref diameter | 2.8 ± 0.4 | 2.8 ± 0.2 | 0.279 |
Data are presented as mean ± SD
BMI Body mass index, HbA1c Glycated hemoglobin, CK-MB Creatine phosphokinase-MB, CRP C-reactive protein, MLD Minimum lumen diameter